Redensyl® vs Minoxidil: The Philpott Test Data (2x Growth Advantage)

Redensyl® is a patented DHQG + EGCG₂ complex developed by Givaudan that simultaneously targets two distinct cell populations: ORSc hair follicle stem cells and HFDPc dermal papilla fibroblasts. In the Philpott ex vivo hair follicle assay, Redensyl® at 1% concentration achieved +214% hair growth versus untreated controls — compared with +118% for Minoxidil at the same concentration. This represents nearly a 2× growth advantage.

The 84-day clinical study enrolled 26 male volunteers with Grade 3–4 androgenetic alopecia. Participants applied Redensyl® at 3% concentration twice daily. Results: +9% anagen hair increase, −17% telogen hair decrease, +8% density increase, and +29% improvement in anagen-to-telogen ratio. 85% of volunteers showed clinically measurable improvement. The average participant gained approximately 10,200 new hairs in three months — more than a single hair transplant session typically delivers.

At the cellular level, DHQG activates ORSc stem cell division with dose-dependent proliferation (p<0.001), maintains stem cell phenotype via K15 upregulation (~2×), provides anti-apoptosis protection via BCL2 (2×), and drives differentiation through β-catenin upregulation (>3×). The EGCG₂ component reduces IL-8 inflammatory cytokine by 21% (p<0.05), calming the follicular microenvironment.